Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF1 | P18846 | 7/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | XPO1 | O14980 | 4/20 | 0.58 |
| ▸ | JUN | P05412 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745582 | 0.89 | CNR2 (0.69) | ATF1NFKB1LMNAXPO1CNR2 | |
| SCHEMBL6990873 | 0.89 | NFKB1 (0.57) | ATF1NFKB1LMNAJUNNFKB2 | |
| SCHEMBL6990055 | 0.81 | TP53 (0.50) | ATF1NFKB1LMNA | |
| SCHEMBL6288117 | 0.80 | ATF1 (0.55) | ATF1NFKB1LMNACNR2GLA | |
| SCHEMBL2307377 | 0.79 | NFKB1 (0.61) | ATF1NFKB1LMNAXPO1JUN | |
| SCHEMBL7489466 | 0.77 | NFKB1 (0.59) | ATF1NFKB1LMNAXPO1JUN | |
| SCHEMBL8544541 | 0.77 | JUN (0.67) | ATF1NFKB1LMNAXPO1JUN | |
| SCHEMBL5079086 | 0.75 | CNR2 (0.84) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3089627 | 0.75 | HTT (0.58) | CNR2GLA | |
| SCHEMBL31023447 | 0.74 | PPARA (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855829-B2 | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1441722-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1361879-A1 | 2,4-DISUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020183335-A1 | Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
| WO-2002072088-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-12 | — | — | US | disclosed |
| WO-2002066036-A1 | 2,4-DISUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | KCNQ5, KCNQ2, KCNQ1 | ATF1 3699/4885NFKB1 1847/4885LMNA 2397/4885 |
| US-20020183335-A1 | Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels | KCNQ5, KCNQ1, KCNQ2 | ATF1 1744/4885NFKB1 1080/4885LMNA 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.